Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 2
2(50.0%)
4Total
N/A(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07481955Phase 2Not Yet Recruiting

Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial

Role: lead

NCT07453069Phase 2Not Yet Recruiting

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

Role: lead

NCT05150639Completed

Vaginal Microbiome and IVF Pregnancy Outcome

Role: lead

NCT05850078Not ApplicableCompleted

FB101 Intervention in Women Screened to Have Vaginal Dysbiosis (Dyscover-3)

Role: lead

NCT05114031Not ApplicableCompleted

FB101 Intervention in Women Screened to Have Vaginal Dysbiosis

Role: lead

All 5 trials loaded